AtriCure, Inc. (NASDAQ:ATRC) Stock Holdings Trimmed by Alliancebernstein L.P.

Alliancebernstein L.P. trimmed its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,835,449 shares of the medical device company's stock after selling 136,999 shares during the quarter. Alliancebernstein L.P. owned about 7.87% of AtriCure worth $117,211,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ATRC. Heck Capital Advisors LLC acquired a new stake in AtriCure during the fourth quarter worth about $60,000. Venturi Wealth Management LLC increased its position in AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after purchasing an additional 2,100 shares in the last quarter. KBC Group NV increased its position in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after purchasing an additional 932 shares in the last quarter. R Squared Ltd purchased a new position in AtriCure in the fourth quarter valued at approximately $89,000. Finally, AlphaQuest LLC lifted its position in AtriCure by 855.1% during the fourth quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock valued at $155,000 after buying an additional 4,532 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ATRC. Canaccord Genuity Group dropped their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. Needham & Company LLC reiterated a "buy" rating and issued a $51.00 price target on shares of AtriCure in a report on Thursday, March 27th. Oppenheimer boosted their price objective on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Stifel Nicolaus increased their target price on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, AtriCure has an average rating of "Moderate Buy" and an average target price of $49.44.

Remove Ads

AtriCure Stock Up 0.9 %

ATRC traded up $0.28 on Monday, reaching $31.59. The company's stock had a trading volume of 691,036 shares, compared to its average volume of 672,064. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The business's 50 day moving average is $37.09 and its 200 day moving average is $34.22. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -33.25 and a beta of 1.65.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.20% of the stock is currently owned by corporate insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.